Review of the waiting list for cadaveric kidney transplant Recipients: A Single institution study

2019 ◽  
Vol 26 (9) ◽  
pp. 1798
Author(s):  
Adem Bayraktar ◽  
Ali Gok
Keyword(s):  
Kidney Transplant ◽  
Waiting List ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Single Institution ◽  
Cadaveric Kidney

scholarly journals Mortality in Elderly Waiting-List Patients Versus Age-Matched Kidney Transplant Recipients: Where is the Risk?

2018 ◽  
Vol 43 (1) ◽  
pp. 256-275 ◽  
Author(s):  
Domingo Hernández ◽  
Juana Alonso-Titos ◽  
Ana María Armas-Padrón ◽  
Pedro Ruiz-Esteban ◽  
Mercedes Cabello ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Waiting List ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals Waiting List and Kidney Transplant Vascular Risk: An Ongoing Unmet Concern

2019 ◽  
Vol 45 (1) ◽  
pp. 1-27 ◽  
Author(s):  
Domingo Hernández ◽  
Juana Alonso-Titos ◽  
Ana Maria Armas-Padrón ◽  
Veronica Lopez ◽  
Mercedes Cabello ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Cardiovascular Risk Factors ◽  
Kidney Transplant ◽  
Mineral Metabolism ◽  
Fibroblast Growth Factor 23 ◽  
Waiting List ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Pathogenic Mechanisms

Background: Chronic kidney disease (CKD) is an important independent risk factor for adverse cardiovascular events in patients waitlisted for kidney transplantation (KT). Although KT reduces cardiovascular risk, these patients still have a higher all-cause and cardiovascular mortality than the general population. This concerning situation is due to a high burden of traditional and nontraditional risk factors as well as uremia-related factors and transplant-specific factors, leading to 2 differentiated processes under the framework of CKD, atherosclerosis and arteriosclerosis. These can be initiated by insults to the vascular endothelial endothelium, leading to vascular calcification (VC) of the tunica media or the tunica intima, which may coexist. Several pathogenic mechanisms such as inflammation-related endothelial dysfunction, mineral metabolism disorders, activation of the renin-angiotensin system, reduction of nitric oxide, lipid disorders, and the fibroblast growth factor 23-klotho axis are involved in the pathogenesis of atherosclerosis and arteriosclerosis, including VC. Summary: This review focuses on the current understanding of atherosclerosis and arteriosclerosis, both in patients on the waiting list as well as in kidney transplant recipients, emphasizing the cardiovascular risk factors in both populations and the inflammation-related pathogenic mechanisms. Key Message: The importance of cardiovascular risk factors and the pathogenic mechanisms related to inflammation in patients waitlisted for KT and kidney transplant recipients.

Long-term evaluation of proliferative donor antigen-specific reactivity in cadaveric kidney transplant recipients

2000 ◽  
Vol 13 (3) ◽  
pp. 187-193
Author(s):  
Georg A. Böhmig ◽  
Marcus D. Säemann ◽  
Michael Bergmann ◽  
Bruno Watschinger ◽  
Heinz Regele ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Term Evaluation ◽  
Specific Reactivity ◽  
Cadaveric Kidney

scholarly journals Long-term evaluation of proliferative donor antigen-specific reactivity in cadaveric kidney transplant recipients

2000 ◽  
Vol 13 (3) ◽  
pp. 187-193 ◽  
Author(s):  
Georg A. Böhmig ◽  
Marcus D. Säemann ◽  
Michael Bergmann ◽  
Bruno Watschinger ◽  
Heinz Regele ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Term Evaluation ◽  
Specific Reactivity ◽  
Cadaveric Kidney

Long-term (≥20 yr) status of 14 cadaveric kidney-transplant recipients

2001 ◽  
Vol 15 (3) ◽  
pp. 199-207 ◽  
Author(s):  
Caroline Delclaux ◽  
Delphine Morel ◽  
Philippe Fernandez ◽  
Pierre Merville ◽  
Colette Deminière ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cadaveric Kidney

scholarly journals MO969IMPACT OF COVID-19 IN KIDNEY REPLACEMENT THERAPY IN AN EPICENTER TERTIARY HOSPITAL IN SOUTHERN BRAZIL

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Pedro do Valle Teichman ◽  
Alessandra Rosa Viccari ◽  
Rodrigo Fontanive Franco ◽  
Maria Luiza Budel da Silva ◽  
Carla Elisabete Da Silva Oliveira ◽  
...  
Keyword(s):  
Replacement Therapy ◽  
Kidney Transplant ◽  
Tertiary Hospital ◽  
Waiting List ◽  
Fatality Rate ◽  
Southern Brazil ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Dialysis Patients ◽  
The Impact

Abstract Background and Aims Patients on renal replacement therapy (RRT) pose multiple risk factors that may increase the risk of death from coronavirus disease 2019 (COVID-19). Currently, evidence of incidence, management, and prognosis of COVID-19 in this population are scarce. Method Between May and December 2020, we followed two RRT populations that have the same tertiary hospital in Southern Brazil as its reference hospital for transplantation. Firstly, we monitored eight affiliated dialysis clinics keeping track of COVID-19 incidence and fatality rate in dialysis patients and those on the kidney transplant waiting list. In the same period, we also monitor COVID-19 incidence and mortality among our prevalent population of kidney transplant recipients. Results We evaluated 1049 patients in RRT in the dialysis centers. COVID-19 occurred in 89 of such patients (8.5%), and 31 died from such condition (35.8% death rate). Fifteen patients (5.45%), among 275 on the kidney transplant waiting list, contracted the virus, with one death (6.6%). Within our prevalent population of 1348 kidney transplant recipients, 113 were diagnosed with COVID19 (incidence: 8.4%), and 17 of them died (mortality rate: 15%). Finally, the number of kidney transplants decreased by 60.4% compared with the same period in the previous year. Conclusion COVID-19 determined a substantial impact on RRT. A high frequency of chronic dialysis patients expired from the disease. The impact on the patients on the transplant waiting list seems to be less pronounced probably due to their better health conditions. The fatality rate in kidney transplant recipients is elevated and probably mostly related to comorbidities. Brazil is currently entering the second wave of the disease and it is crucial to find and provide means to protect such vulnerable populations.

scholarly journals Impact of Navigators on First Visit to a Transplant Center, Waitlisting, and Kidney Transplantation

2018 ◽  
Vol 13 (10) ◽  
pp. 1550-1555 ◽  
Author(s):  
Catherine M. Sullivan ◽  
Kitty V. Barnswell ◽  
Kate Greenway ◽  
Cindy M. Kamps ◽  
Derrick Wilson ◽  
...  
Keyword(s):  
Confidence Interval ◽  
Kidney Transplant ◽  
Living Donor ◽  
Waiting List ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Transplant Center ◽  
And Control ◽  
Trial Intervention ◽  
Donor Transplant

Background and objectivesMany patients with ESKD face barriers in completing the steps required to obtain a transplant. These eight sequential steps are medical suitability, interest in transplant, referral to a transplant center, first visit to center, transplant workup, successful candidate, waiting list or identify living donor, and receive transplant. This study sought to determine the effect of navigators on helping patients complete these steps.Design, setting, participants, & measurementsOur study was a cluster randomized, controlled trial involving 40 hemodialysis facilities and four transplant centers in Ohio, Kentucky, and Indiana from January 1, 2014 to December 31, 2016. Four trained kidney transplant recipients met regularly with patients on hemodialysis at 20 intervention facilities, determined their step in the transplant process, and provided tailored information and assistance in completing that step and subsequent steps. Patients at 20 control facilities continued to receive usual care. Primary study outcomes were waiting list placement and receipt of a deceased or living donor transplant. An exploratory outcome was first visit to a transplant center.ResultsBefore the trial, intervention (1041 patients) and control (836 patients) groups were similar in the proportions of patients who made a first visit to a transplant center, were placed on a waiting list, and received a deceased or living donor transplant. At the end of the trial, intervention and control groups were also similar in first visit (16.1% versus 13.8%; difference, 2.3%; 95% confidence interval, −0.8% to 5.5%), waitlisting (16.3% versus 13.8%; difference, 2.5%; 95% confidence interval, −1.2% to 6.1%), deceased donor transplantation (2.8% versus 2.2%; difference, 0.6%; 95% confidence interval, −0.8% to 2.1%), and living donor transplantation (1.2% versus 1.0%; difference, 0.1%; 95% confidence interval, −0.9% to 1.1%).ConclusionsUse of trained kidney transplant recipients as navigators did not increase first visits to a transplant center, waiting list placement, and receipt of deceased or living donor transplants.

Generalized Seizures Associated with the Use of Muromonab-CD3 in Two Patients after Kidney Transplantation

1997 ◽  
Vol 31 (5) ◽  
pp. 586-589 ◽  
Author(s):  
Raafat A Seifeldin ◽  
Kenneth R Lawrence ◽  
Anisha F Rahamtulla ◽  
Anthony P Monaco
Keyword(s):  
Kidney Transplantation ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Case Summary ◽  
Generalized Seizures ◽  
Uremic Patients ◽  
Cadaveric Kidney

OBJECTIVE: TO report two cases of seizures associated with the use of muromonab-CD3. CASE SUMMARY: TWO uremic cadaveric kidney transplant recipients had developed generalized seizures following administration of muromonab-CD3 within the first 2 days after transplantation. Seizures were treated successfully with intravenous phenytoin, and muromonab-CD3 administration was discontinued. DISCUSSION: The overall frequency of seizures during muromonab-CD3 administration is 6%. Uremia in patients in the early posttransplant period appears to predispose them to seizures. Seizures that happened to our two uremic patients after transplant suggest that they had been induced by muromonab-CD3 administration. The mechanism of how this could have induced seizures is unknown. CONCLUSIONS: Prophylactic muromonab-CD3 should be used carefully in uremic kidney transplant recipients following surgery. If therapy with muromonab-CD3 is necessary, early hemodialysis should be considered in an effort to lower the risk of seizures.

Sign in / Sign up

Export Citation Format

Share Document